We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
Ligand Pharmaceuticals (LGND - Free Report) closed at $58.84 in the latest trading session, marking a +1.19% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.63%. Elsewhere, the Dow saw an upswing of 0.59%, while the tech-heavy Nasdaq appreciated by 0.39%.
Heading into today, shares of the drugmaker had lost 7.77% over the past month, lagging the Medical sector's loss of 1.62% and the S&P 500's loss of 3.39% in that time.
The investment community will be closely monitoring the performance of Ligand Pharmaceuticals in its forthcoming earnings report. The company is forecasted to report an EPS of $0.68, showcasing a 65.85% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $27.11 million, down 58.98% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $5.09 per share and revenue of $125 million, which would represent changes of +6.26% and -43.07%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Ligand Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.4% higher. As of now, Ligand Pharmaceuticals holds a Zacks Rank of #3 (Hold).
Digging into valuation, Ligand Pharmaceuticals currently has a Forward P/E ratio of 11.42. This indicates a discount in contrast to its industry's Forward P/E of 17.38.
We can additionally observe that LGND currently boasts a PEG ratio of 0.57. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. LGND's industry had an average PEG ratio of 2.13 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 83, finds itself in the top 33% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider
Ligand Pharmaceuticals (LGND - Free Report) closed at $58.84 in the latest trading session, marking a +1.19% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.63%. Elsewhere, the Dow saw an upswing of 0.59%, while the tech-heavy Nasdaq appreciated by 0.39%.
Heading into today, shares of the drugmaker had lost 7.77% over the past month, lagging the Medical sector's loss of 1.62% and the S&P 500's loss of 3.39% in that time.
The investment community will be closely monitoring the performance of Ligand Pharmaceuticals in its forthcoming earnings report. The company is forecasted to report an EPS of $0.68, showcasing a 65.85% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $27.11 million, down 58.98% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $5.09 per share and revenue of $125 million, which would represent changes of +6.26% and -43.07%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Ligand Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.4% higher. As of now, Ligand Pharmaceuticals holds a Zacks Rank of #3 (Hold).
Digging into valuation, Ligand Pharmaceuticals currently has a Forward P/E ratio of 11.42. This indicates a discount in contrast to its industry's Forward P/E of 17.38.
We can additionally observe that LGND currently boasts a PEG ratio of 0.57. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. LGND's industry had an average PEG ratio of 2.13 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 83, finds itself in the top 33% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.